Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an <i>In Vitro</i> Pharmacodynamic Model
Maya Beganovic, Kathryn E Daffinee, Megan K. Luther, Kerry L. LaPlante
Abstract
Acinetobacter baumannii is recognized as an urgent public health threat by the Centers for Disease Control and Prevention (CDC). Current treatment options are scarce, particularly against carbapenem-resistant Acinetobacter baumannii (CRAB).
Topics & Concepts
Acinetobacter baumanniiMeropenemSulbactamMicrobiologyCarbapenemPolymyxinMedicineColistinMinocyclineAcinetobacterPolymyxin BAntibioticsBiologyPseudomonas aeruginosaAntibiotic resistanceImipenemBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance